{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:06:44Z","timestamp":1793394404105,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15215-4","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:01:08Z","timestamp":1764943268000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dynamic CEA kinetics as a prognostic biomarker for HER2-negative advanced gastric cancer treated with chemoimmunotherapy"],"prefix":"10.1186","volume":"25","author":[{"given":"Shuixiu","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changchun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"3","key":"15215_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"issue":"10251","key":"15215_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet (London England). 2020;396(10251):635\u201348.","journal-title":"Lancet (London England)"},{"issue":"3","key":"15215_CR3","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cgh.2019.07.045","volume":"18","author":"AP Thrift","year":"2020","unstructured":"Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association. 2020;18(3):534\u201342.","journal-title":"Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association"},{"issue":"Suppl 1","key":"15215_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s10120-016-0648-7","volume":"20","author":"K Shitara","year":"2017","unstructured":"Shitara K. Chemotherapy for advanced gastric cancer: future perspective in Japan. Gastric Cancer: Official J Int Gastric Cancer Association Japanese Gastric Cancer Association. 2017;20(Suppl 1):102\u201310.","journal-title":"Gastric Cancer: Official J Int Gastric Cancer Association Japanese Gastric Cancer Association"},{"issue":"9","key":"15215_CR5","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","volume":"3","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, Schmalenberg H, Luley KB, Prasnikar N, Egger M, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol. 2017;3(9):1237\u201344.","journal-title":"JAMA Oncol"},{"issue":"25","key":"15215_CR6","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, et al. Trastuzumab Deruxtecan in previously treated HER2-Positive gastric cancer. N Engl J Med. 2020;382(25):2419\u201330.","journal-title":"N Engl J Med"},{"issue":"6","key":"15215_CR7","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","volume":"17","author":"K Muro","year":"2016","unstructured":"Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17(6):717\u201326.","journal-title":"Lancet Oncol"},{"issue":"10294","key":"15215_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet (London England). 2021;398(10294):27\u201340.","journal-title":"Lancet (London England)"},{"issue":"2","key":"15215_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234\u201347.","journal-title":"Lancet Oncol"},{"issue":"11","key":"15215_CR10","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395.","journal-title":"Lancet Oncol"},{"key":"15215_CR11","first-page":"e078876","volume":"385","author":"MZ Qiu","year":"2024","unstructured":"Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, Zimina AV, Bai Y, Shi J, Lee KW, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ (Clinical Res ed). 2024;385:e078876.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"1","key":"15215_CR12","first-page":"117","volume":"31","author":"Diagnosis","year":"2019","unstructured":"Diagnosis, Treatment Guidelines For Colorectal Cancer Working Group C. Chinese society of clinical oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version). Chin J Cancer Res = Chung-kuo Yen Cheng Yen Chiu. 2019;31(1):117\u201334.","journal-title":"Chin J Cancer Res = Chung-kuo Yen Cheng Yen Chiu"},{"issue":"26","key":"15215_CR13","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.3748\/wjg.v24.i26.2818","volume":"24","author":"T Matsuoka","year":"2018","unstructured":"Matsuoka T, Yashiro M. Biomarkers of gastric cancer: current topics and future perspective. World J Gastroenterol. 2018;24(26):2818\u201332.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"15215_CR14","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A, Smyth EC. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Annals Oncology: Official J Eur Soc Med Oncol. 2022;33(10):1005\u201320.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"11","key":"15215_CR15","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1002\/ijc.28384","volume":"134","author":"MJ Duffy","year":"2014","unstructured":"Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousov\u00e1 M, Holubec L, Sturgeon C. Tumor markers in colorectal cancer, gastric cancer and Gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 2014;134(11):2513\u201322.","journal-title":"Int J Cancer"},{"issue":"9","key":"15215_CR16","doi-asserted-by":"publisher","first-page":"e503","DOI":"10.1111\/codi.12304","volume":"15","author":"JW Park","year":"2013","unstructured":"Park JW, Chang HJ, Kim BC, Yeo HY, Kim DY. Clinical validity of tissue carcinoembryonic antigen expression as ancillary to serum carcinoembryonic antigen concentration in patients curatively resected for colorectal cancer. Colorectal Dis. 2013;15(9):e503\u2013511.","journal-title":"Colorectal Dis"},{"issue":"4","key":"15215_CR17","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S0002-9610(01)00585-2","volume":"181","author":"N Abe","year":"2001","unstructured":"Abe N, Watanabe T, Toda H, Machida H, Suzuki K, Masaki T, Mori T, Sugiyama M, Atomi Y, Nakaya Y. Prognostic significance of carcinoembryonic antigen levels in peritoneal washes in patients with gastric cancer. Am J Surg. 2001;181(4):356\u201361.","journal-title":"Am J Surg"},{"issue":"4","key":"15215_CR18","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1245\/s10434-015-4981-6","volume":"23","author":"W Wang","year":"2016","unstructured":"Wang W, Seeruttun SR, Fang C, Chen J, Li Y, Liu Z, Zhan Y, Li W, Chen Y, Sun X, et al. Prognostic significance of carcinoembryonic antigen staining in cancer tissues of gastric cancer patients. Ann Surg Oncol. 2016;23(4):1244\u201351.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"15215_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/cam4.3616","volume":"10","author":"Y Miki","year":"2021","unstructured":"Miki Y, Yashiro M. Circulating CEA-positive and EpCAM-negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer. Cancer Med. 2021;10(2):521\u20138.","journal-title":"Cancer Med"},{"issue":"2","key":"15215_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1272\/jnms.JNMS.2022_89-212","volume":"89","author":"T Kawagoe","year":"2022","unstructured":"Kawagoe T, Ikeda G, Oshiro Y, Kaneko K, Iwakiri K. A proposed new clinical classification of metastatic gastric cancer: pyloric and antral gastric cancer. J Nippon Med Sch. 2022;89(2):176\u201383.","journal-title":"J Nippon Med Sch"},{"issue":"7624","key":"15215_CR21","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ (Clinical Res ed). 2007;335(7624):806\u20138.","journal-title":"BMJ (Clinical Res ed)"},{"key":"15215_CR22","first-page":"g7594","volume":"350","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ (Clinical Res ed). 2015;350:g7594.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"20","key":"15215_CR23","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. Declaration of helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"key":"15215_CR24","doi-asserted-by":"crossref","unstructured":"Mranda GM, Xue Y, Zhou XG, Yu W, Wei T, Xiang ZP, Liu JJ, Ding YL. Revisiting the 8th AJCC system for gastric cancer: A review on validations, nomograms, lymph nodes impact, and proposed modifications. Annals of medicine and surgery (2012) 2022, 75:103411.","DOI":"10.1016\/j.amsu.2022.103411"},{"issue":"2","key":"15215_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford England: 1990). 2009;45(2):228\u201347.","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"15215_CR26","unstructured":"Common Terminology. Criteria for Adverse Events (CTCAE) Version 5.0. 2017."},{"issue":"7890","key":"15215_CR27","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Kawazoe A, Ya\u00f1ez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 Blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727\u201330.","journal-title":"Nature"},{"issue":"1","key":"15215_CR28","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US food and drug administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"15215_CR29","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/cas.14798","volume":"112","author":"K Akagi","year":"2021","unstructured":"Akagi K, Oki E. Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci. 2021;112(3):1105\u201313.","journal-title":"Cancer Sci"},{"issue":"2","key":"15215_CR30","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/jgh.13059","volume":"31","author":"BS Lee","year":"2016","unstructured":"Lee BS, Lee SH, Son JH, Jang DK, Chung KH, Paik WH, Ryu JK, Kim YT. Prognostic value of CA 19\u2009\u2013\u20099 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma. J Gastroenterol Hepatol. 2016;31(2):493\u2013500.","journal-title":"J Gastroenterol Hepatol"},{"key":"15215_CR31","doi-asserted-by":"publisher","first-page":"8704751","DOI":"10.1155\/2018\/8704751","volume":"2018","author":"H Xing","year":"2018","unstructured":"Xing H, Wang J, Wang Y, Tong M, Hu H, Huang C, Li D. Diagnostic value of CA 19\u2009\u2013\u20099 and carcinoembryonic antigen for pancreatic cancer: A Meta-Analysis. Gastroenterol Res Pract. 2018;2018:8704751.","journal-title":"Gastroenterol Res Pract"},{"issue":"6","key":"15215_CR32","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.asjsur.2020.12.031","volume":"44","author":"SH Park","year":"2021","unstructured":"Park SH, Shin JH, Jung KU, Lee SR. Prognostic value of carcinoembryonic antigen and carbohydrate antigen 19\u2009\u2013\u20099 in periampullary cancer patients receiving pancreaticoduodenectomy. Asian J Surg. 2021;44(6):829\u201335.","journal-title":"Asian J Surg"},{"issue":"6","key":"15215_CR33","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1080\/17512433.2017.1313113","volume":"10","author":"M Bonotto","year":"2017","unstructured":"Bonotto M, Garattini SK, Basile D, Ongaro E, Fanotto V, Cattaneo M, Cortiula F, Iacono D, Cardellino GG, Pella N, et al. Immunotherapy for gastric cancers: emerging role and future perspectives. Expert Rev Clin Pharmacol. 2017;10(6):609\u201319.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"15215_CR34","doi-asserted-by":"crossref","unstructured":"Peker P, Ge\u00e7gel A, \u00d6zkan O, et al. Systemic Immune-Inflammation Index as a Prognostic Marker in Gastric and Gastroesophageal Junction Cancers Receiving Perioperative FLOT Therapy. Med (Kaunas Lithuania). 2025;61(9):1614.","DOI":"10.3390\/medicina61091614"},{"issue":"9","key":"15215_CR35","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563\u201380.","journal-title":"Nat Rev Clin Oncol"},{"issue":"35","key":"15215_CR36","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S. Management of Immune-Related adverse events in patients treated with chimeric antigen receptor T-Cell therapy: ASCO guideline. J Clin Oncology: Official J Am Soc Clin Oncol. 2021;39(35):3978\u201392.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"1","key":"15215_CR37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-020-00886-2","volume":"13","author":"F Wang","year":"2020","unstructured":"Wang F, Qin S, Sun X, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. J Hematol Oncol. 2020;13(1):47.","journal-title":"J Hematol Oncol"},{"key":"15215_CR38","doi-asserted-by":"publisher","first-page":"1248790","DOI":"10.3389\/fonc.2023.1248790","volume":"13","author":"Y Xiong","year":"2023","unstructured":"Xiong Y, Mo P, Yan Y, Wang S, Zhuang K, Ma Z, Chen X, Deng L, Xiong Y, Deng D, et al. The safety and efficacy of PD-1 inhibitors in patients with advanced cancers and HIV\/AIDS in China. Front Oncol. 2023;13:1248790.","journal-title":"Front Oncol"},{"issue":"2","key":"15215_CR39","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, et al. Gastric Cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Network: JNCCN. 2022;20(2):167\u201392.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"key":"15215_CR40","doi-asserted-by":"publisher","first-page":"880419","DOI":"10.3389\/fonc.2022.880419","volume":"12","author":"H Song","year":"2022","unstructured":"Song H, Sun H, Yang L, Gao H, Cui Y, Yu C, Xu H, Li L. Nutritional risk index as a prognostic factor predicts the clinical outcomes in patients with stage III gastric cancer. Front Oncol. 2022;12:880419.","journal-title":"Front Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15215-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15215-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15215-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:01:10Z","timestamp":1764943270000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15215-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15215"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15215-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by Jingjiang People\u2019s Hospital Affiliated to Yangzhou University, and the requirement for individual informed consent was waived due to the retrospective nature of the study. All procedures were performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"1857"}}